Anti-OLFM4 antibodies are immunoglobulins that specifically recognize and bind OLFM4, the gene encoding olfactomedin-4 in humans. In research applications, these antibodies are used to detect OLFM4 in tissue samples, cell lysates, and cultured cells. OLFM4 facilitates cell adhesion through interactions with cell-surface lectins and cadherins and shows context-dependent effects on cell growth, promoting proliferation in some epithelial cancers while inducing differentiation and apoptosis in myeloid leukemic cell lines. OLFM4 is widely used as a marker of intestinal crypt base columnar stem cells and is studied in the progression of gastric intestinal metaplasia and related premalignant conditions.
Catalog highlights and purchasing considerations
About the Biocompare OLFM4 antibody catalog
The Biocompare antibody search tool lists anti-OLFM4 antibodies from a range of suppliers, spanning unconjugated and fluorophore- or enzyme-conjugated formats. Listings may also appear under the alternate name GW112. Western blot is the most common validated application among these listings, followed by ELISA and immunohistochemistry. Several OLFM4 antibodies mentioned here have been cited across a range of gastrointestinal research, including studies on OLFM4-expressing cell populations in gastric intestinal metaplasia, intestinal stem cell aging and regeneration, and spatial transcriptomic mapping of premalignant gastric niches.
Considerations when choosing an OLFM4 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, is widely regarded as the most reliable final check before purchase.